Effects of rituximab in connective tissue disorders related interstitial lung disease

Clinical and Experimental Rheumatology

Volumn 34, Issue , 2016, Pages 181-185

  Lepri, Gemma ^a,b   Avouac, Jerome ^b   Airò, Paolo ^c   Santos, Francisco Anguita ^d   Bellando Randone, Silvia ^a   Blagojevic, Jelena ^a   Hernàndez, Francisco Garcia ^e   Gonzalez Nieto, José Antonio ^f   Guiducci, Serena ^a   Jordan, Suzana ^g   Limaye, Vidya ^h   Maurer, Britta ^g   Selva O'Callaghan, Albert ⁱ   Riccieri, V ^j   Distler, Oliver ^g   Matucci Cerinic, Marco ^a   Allanore, Yannick ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF BRESCIA   (Italy)

^d HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f HOSPITAL CAN MISSES   (Spain)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h UNIVERSITY OF ADELAIDE   (Australia)

ⁱ UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

more..

Author keywords

Anti synthetase syndrome; Lung involvement; Mixed connective tissue disease; Rituximab; Systemic sclerosis; Therapy

Indexed keywords

AZATHIOPRINE; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISONE; RITUXIMAB;

ADULT; ANTISYNTHETASE SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HEART ARRHYTHMIA; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; MALE; MIXED CONNECTIVE TISSUE DISEASE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SERUM SICKNESS; SYSTEMIC SCLEROSIS; AGED; CLINICAL TRIAL; COMPLICATION; CONNECTIVE TISSUE DISEASES; CONVALESCENCE; DISEASE COURSE; DRUG EFFECTS; LUNG; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME; VITAL CAPACITY;

ADULT; AGED; CONNECTIVE TISSUE DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; RITUXIMAB; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84994444363     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. GUTSCHE M, ROSEN GD, SWIGRIS JJ: Connective Tissue Disease-associated Interstitial Lung Disease: A review. Curr Respir Care Rep 2013; 1: 224-32.
2. MORGENTHAU AS, PADILLA ML: Spectrum of fibrosis diffuse parenchymal lung disease. Mt Sinai J Med 2009; 76: 2-23.
3. GUNNARSSON R, AALØKKEN TM, MOLBERG Ø et al.: Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis 2012; 71: 1966-72.
4. STEEN VD, MEDSGER TA Jr.: Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44.
5. VANDENBROUCKE E, GRUTTERS JC, ALTENBURG J et al.: Rituximab in life threatening antisynthetase syndrome. Rheumatol Int 2009; 29: 1499-502.
6. KAWANO-DOURADO L, BALDI BG, KAY FU et al.: Pulmonary involvement in long-term mixed connective issue disease: functional trends and image findings after 10 years. Clin Exp Rheumatol 2015; 33: 234-40.
7. MOORE O, PROUDMAN S, GOH N et al.: Quantifying change in pulmonary function as a prognostic marker in systemic sclerosisrelated interstitial lung disease. Clin Exp Rheumatol 2015; 33 (Suppl. 91): S111-6.
8. BOUROS D, WELLS AU, NICHOLSON AG et al.: Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-6.
9. MARIE I, HACHULLA E, CHéRIN P et al.: Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47: 614-22.
10. JORDAN S, DISTLER JH, MAURER B et al.: Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015; 74: 1188-94.
11. DAOUSSIS D, LIOSSIS SC, TSAMANDAS AC et al.: Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012; 30 (Suppl. 71): S17-S22.
12. BOSELLO SL, DE LUCA G, RUCCO M et al.: Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum 2015; 44: 428-36.
13. MARIE I, DOMINIQUE S, JANVRESSE A et al.: Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Resp Med 2012; 106: 518-7.
14. Van den HOOGEN F, KHANNA D, FRANSEN J et al.: 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-47.
15. CAPPELLI S, BELLANDO RANDONE S, MARTINOVIC D et al.: "To Be or Not To Be," Ten Years After: Evidence for Mixed Connective Tissue Disease as a Distinct Entity. Semin Arthritis Rheum 2012; 41: 589-98.
16. NOBLE PW, ALBERA C, BRADFORD WZ et al.: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-9.
17. ANDERSSON H, SEM M, LUND MB et al.: Long-term experience with rituximab in antisynthetase syndrome-related interstitial lung disease. Rheumatology (Oxford) 2015; 54: 1420-8.
18. GOLDIN J, ELASHOFF R, KIM HJ et al.: Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 2009; 136: 1333-40.
19. WANCHU A, SURYANARYANA BS, SHARMA S et al.: High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study. Int J Rheum Dis 2009; 12: 239-42.
20. MOAZEDI-FUERST FC, KIELHAUSER SM, BRICKMANN K et al.: Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases Results of a lower dosage and shorter interval regimen. Scand J Rheumatol 2014; 43: 257-8.